Equities

Inhibitor Therapeutics Inc

INTI:QBB

Inhibitor Therapeutics Inc

Actions
  • Price (USD)0.1206
  • Today's Change-0.009 / -7.22%
  • Shares traded313.00
  • 1 Year change+242.18%
  • Beta-0.5996
Data delayed at least 15 minutes, as of May 09 2024 16:24 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Inhibitor Therapeutics, Inc. is a pharmaceutical development company. The Company is focused on developing and commercializing therapeutics based on already approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery for patients with certain cancers and certain non-cancerous proliferation disorders. Its primary focus is on the development of therapies initially for basal cell carcinoma (BCC), prostate and lung cancers in the United States utilizing itraconazole, a drug approved by the United States Food and Drug Administration (FDA) to treat fungal infections. The Company has developed intellectual property and know-how related to the treatment of cancer patients using itraconazole. The Company's intellectual property in the form of issued United States patents includes treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors, and treatment of lung cancer using hedgehog pathway inhibitors.

  • Revenue in USD (TTM)0.00
  • Net income in USD-3.03m
  • Incorporated2013
  • Employees3.00
  • Location
    Inhibitor Therapeutics Inc4830 W. Kennedy Blvd., Suite 600TAMPA 33609United StatesUSA
  • Phone+1 (813) 766-2462
  • Fax+1 (813) 527-0500
  • Websitehttps://inhibitortx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
MEI Pharma Inc72.65m19.84m21.05m46.001.060.35391.040.28982.982.9810.908.930.6425--25.471,579,304.0017.55-25.3120.31-28.59----27.32-122.05----0.00--19.9597.5641.53------
Alaunos Therapeutics Inc5.00k-35.14m21.14m1.00--3.35--4,227.29-2.20-2.200.00030.39390.0001--2.005,000.00-96.01-74.83-149.28-89.57-----702,800.00-10,508.06---14.830.00---99.83-49.086.86---15.56--
Synlogic Inc3.37m-57.28m21.22m6.00--0.393--6.29-11.41-11.410.65814.640.0362----561,833.30-61.46-40.57-74.45-43.82-----1,699.26-3,245.93----0.00009--185.685.9913.40---48.05--
Neurosense Therapeutics Ltd0.00-11.28m21.32m16.00---------0.7625-0.76250.00-0.12190.00----0.00-207.24---395.72----------------------8.59------
AIM ImmunoTech Inc202.00k-28.96m21.63m26.00--2.19--107.09-0.595-0.5950.00420.20840.0068--0.14137,769.23-96.75-45.64-116.18-48.3579.21-231.75-14,337.62-11,695.01----0.00--43.26-11.26-48.94--35.73--
Inhibitor Therapeutics Inc0.00-3.03m22.36m3.00--4.23-----0.0176-0.01760.000.03070.00----0.00-28.9227.48-30.9132.70------------0.000.00-----125.39------
Zivo Bioscience Inc27.65k-7.78m22.40m8.00------809.98-4.62-4.620.0163-0.92590.0206----3,456.25-580.66-376.60----41.99---28,127.23-96,315.32---97.39--------11.07------
Vincerx Pharma Inc0.00-40.16m22.75m42.00--1.58-----1.89-1.890.000.52420.00----0.00-103.63---128.01--------------0.00------36.24------
Lisata Therapeutics Inc0.00-20.84m22.85m25.00--0.4655-----2.58-2.580.005.910.00----0.00-32.63-45.97-36.16-50.47------------0.00------61.57------
Bullfrog AI Holdings, Inc.65.00k-5.36m23.08m4.00--6.91--355.09-0.9042-0.90420.01080.42530.0455----16,250.00-374.94------92.00---8,239.82-----67.870.00--550.00---91.11------
Qilian International Holding Group Ltd46.47m-7.78m23.24m298.00--0.543--0.50-0.2176-0.21761.301.200.80276.4533.30155,944.60-14.032.71-16.843.863.7711.66-17.482.724.43-0.48120.010726.11-28.35-1.60-822.64--12.86--
TherapeuticsMD Inc1.30m-7.70m23.41m1.00--0.7993--17.98-0.7466-1.000.12492.540.0195----1,302,000.00-11.51-53.35-19.23-111.61100.0086.67-591.32-236.57----0.00---98.14-39.53-816.85------
Cumberland Pharmaceuticals, Inc.39.55m-6.28m23.67m91.00--0.7967--0.5986-0.4448-0.44482.752.100.45280.83833.45434,643.10-7.25-7.03-10.66-9.5284.6679.95-16.01-17.641.11-25.080.3041---5.856.15-12.73---36.17--
Lyra Therapeutics Inc1.68m-68.88m23.76m109.00--0.3066--14.15-1.23-1.230.02971.270.0143----19,090.91-58.52-58.01-68.02-68.69-----4,099.82-6,235.31----0.00--14.314.60-13.39--95.14--
Eom Pharmaceutical Holdings Inc0.00-4.93m23.79m3.00---------0.0435-0.04350.00-0.0212------0.00---126.34---171.37------------7.41-------254.37------
bioAffinity Technologies Inc2.53m-7.94m23.83m75.00--4.01--9.41-0.9036-0.90360.28950.51680.2482144.956.1633,766.67-77.80---93.28--31.26---313.41--1.76--0.1983--52,660.42--2.66------
Data as of May 09 2024. Currency figures normalised to Inhibitor Therapeutics Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.